Locus 56: SLC22A1|SLC22A2 (6q25.3)
| Meta-analysis summary statistics for associations meeting genome-wide significance |
| Lead SNP | Biochemicals | EA/OA | Ntotal | EAF | Effect (SE) | Pmeta | Details |
| rs316020 |
X-12798 / phenylalanine |
A/G |
7100 |
0.09 |
-0.183 (0.005) |
2.77·10-286 |
show |
| rs316019 |
X-12798 |
A/C |
7119 |
0.09 |
-0.181 (0.005) |
1.56·10-259 |
show |
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations |
| SNP | rs316020 |
| Chromosomal location | Chr6: 160,589,071 (6q25.3) |
| Gene (distance) | SLC22A2 (0) |
| Predicted causal gene | SLC22A1 |
| Gene/protein classification | transporter/transporter |
| Metabolite (Pathway) | X-12798 (Unknown) phenylalanine (Phenylalanine & tyrosine metabolism; Amino acid) |
| Biochemical locus-metabolite relationship | SLC22A1 and SLC22A2 encode the Oct1 and Oct2 organic cation transporters. These transporters are not known to specifically transport phenylalanine, but Oct1 has been shown to transport dopamine, a neurotransmitter which can be synthesized from phenylalanine [9260930]. Ratio interpretation: n/a. |
| eQTL associations | - |
| Medical information |
| Complex trait associations | - |
| Known metabolite associations | X-12798 [23093944] |
| Inborn error of metabolism | - |
| Pharmacological information |
| ChEMBL ID | CHEMBL5685, CHEMBL1743122 |
| Drug information |
Substrates of SLC22A1: Tetraethylammonium, N-methylpyridinium, metformin*, oxaliplatin; Inhibitors of SLC22A1: Quinine, quinidine, disopyramide; Substrates of SLC22A2: N-Methylpyridinium, tetraethylammonium, metformin*, pindolol, procainamide, ranitidine amantadine, amiloride, oxaliplatin, varenicline; Inhibitors of SLC22A2: Cimetidine*, pilsicainide, cetirizine*, testosterone, quinidine; (PMID: 20190787)
|
| Locus information for top associated metabolite |
HapMap2 imputation | 1KGP imputation |

